February 13, 2024 · Form 4 insider transaction
GORMAN KEVIN CHARLES sold 2,832 shares of Neurocrine Biosciences, Inc. at $133.02 per share, a transaction worth $376.7K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Sale of 2,832 shares of common stock issued upon vesting of 5,376 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,544) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.; Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.98 to $134.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.; 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.